Contra: "Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery"

Thrombosis and Haemostasis

Volumn 108, Issue 2, 2012, Pages 210-212

  Douketis, James D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; ELECTIVE SURGERY; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; RISK FACTOR; STROKE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; THROMBOEMBOLISM; WARFARIN;

EID: 84864364311     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-04-0236     Document Type: Article

References (24)

1. th Edition). Chest 2012; 141 (2 Suppl): e326S-350S.
2. O'Donnell MJ, Kearon C, Johnson J, et al. Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 2007; 146: 184-187.
3. Douketis JD, Woods K, Foster GA, et al. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005; 94: 528-531.
4. Pengo V, Cucchini U, Denas G, et al. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009; 119: 2920-2927.
5. Malato A, Saccullo G, Lo Coco L, et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost 2010; 8: 107-113.
6. Halbritter KM, Wawer A, Beyer J, Oettler W, Schellong SM. Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective 1 year registry of 311 episodes. J Thromb Haemost 2005; 3: 2823-2825.
7. Dunn AS, Spyropoulos A, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 2007; 5: 2211-2218.
8. National Institutes of Health Clinical Center. A safety and effectiveness study of LMWH bridging therapy versus placebo bridging therapy for patients on long term warfarin and require temporary interruption of their warfarin. NCT00432796. ClinicalTrials. gov. Bethesda, MD: National Institutes of Health; 2007.
9. National Institutes of Health Clinical Center. Effectiveness of bridging anticoagulation for surgery. NCT00786474. ClinicalTrials. gov. Bethesda, MD: National Institutes of Health; 2008.
10. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-1511.
11. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168: 63-69.
12. Daniels PR, McBane RD, Litin SC, et al. Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res 2009; 124: 300-305.
13. Wysokinski WE, McBane RD, Daniels PR, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 2008; 83: 639-645.
14. th Edition). Chest 2008; 133: 299S-339S.
15. Jaffer AK, Ahmed M, Brotman DJ, et al. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 2005; 20: 11-16.
16. Tafur AJ, McBane R II, Wysokinski WE, et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 2012; 10: 261-267.
17. Yudin J, Siegal D, Lim W, et al. Perioperative heparin bridging in patients receiving oral anticoagulation: meta-analysis of bleeding and thromboembolic rates. Blood 2011; 118: 545.
18. Kaatz S, Douketis JD, Zhou H, et al. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 2010; 8: 884-890.
19. Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996; 92: 479-485.
20. López Y, Páramo JA, Valentí JR, Pardo F, Montes R, Rocha E. Hemostatic markers in surgery: a different fibrinolytic activity may be of pathophysiological significance in orthopedic versus abdominal surgery. Int J Clin Lab Res 1997; 27: 233-237.
21. Kosir MA, Schmittinger L, Barno-Winarski L, et al. Prospective double-arm study of fibrinolysis in surgical patients. J Surg Res 1998; 74: 96-101.
22. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing noncardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371: 1839-1847.
23. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
24. NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297.